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OBJECTIVES: Epilepsy is common chronic disorder characterized by recurrent 
unprovoked seizures with incidence rate of 20 to 70 per 100 000 population per 
year. Approximately 150,000 children sustain a first-time unprovoked seizure every 
year, and of those, 30,000 develop epilepsy. To evaluate the economic burden of pedi-
atric epileptic patients and cost of their epilepsy management from the patients’ 
perspective. METHODS: This study adopted a prospective cross sectional design by 
interviewing the patient’s parents from neurology clinic of Hospital Pulau Pinang, 
Malaysia. A retrospective data (for the past 12 months) was collected from patient’s 
medical record for the laboratory test, investigations and treatment received. The 
collected data included information about the patient’s resources utilization, lost 
productivity, and out of pocket expenditure. RESULTS: Majority of respondent was 
male which comprise of 64.2% whereby female was 35.8%. Mean (±SD) total annual 
cost from patient perspective was RM 1303.05 ± 2288.66 (USD 366.69±644.06) per 
patient. The highest item cost which contributes to the total annual cost was the 
loss of productivity which is RM 528.26 ± 786.22 (USD 148.66±221.25) followed by cost 
of caretaker RM 690.32 ± 1929.41 (USD 194.26±542.96) and meal/snack cost during 
clinic visit RM 44.97±56.87 (USD 12.66±16). The lowest contributor for annual cost 
from patient perspective was transportation cost with a mean of RM 39.51 ± 31.73 
(USD 11.22±8.93). CONCLUSIONS: In conclusion, from patients’ perspectives loss of 
productivity is the major contributor in economic burden to epilepsy management 
in pediatric. Type of seizure associated with neurological deficit and the response 
to the medication which affects the number of clinic visit, number of hospitaliza-
tion and length of hospital admission influence lifetime cost of epilepsy bear by 
the patient depending on employment and monthly incomes as well as who is the 
caretaker and who bring the child to clinic visit and accompanied the child during 
hospital admission.
PND28
aNalysis Of meDical cOsts Of rrms relaPses
Nakamura Y.
Milliman, Tokyo, Japan
OBJECTIVES: No recent study on the medical costs of multiple-sclerosis (MS) 
has employed real world data to analyze relapsing-remitting multiple sclerosis 
(RRMS) and primary progressive multiple sclerosis (PPMS). This paper analyzes 
the medical costs of RRMS to identify the causes of the high medical costs of 
MS. METHODS: We selected subjects from among active employees and their fam-
ilies who were covered by private health insurance from MedStat Commercial Data 
from 2005 to 2012. We developed logic to identify MS patients, MS relapses and 
RRMS patients and PPMS patients with claims data. The PPPM of RRMS patients 
was analyzed in cases where relapsing intervals were greater than the average 
interval length. RESULTS: The PPPM of RRMS patients was $4,964 PPPM. The fre-
quency of RRMS relapses was 3.2 times during 5 years. The PPPM of RRMS patients 
was reduced by $958 PPPM when relapsing intervals were increased by 1.2 times 
compared to the usual RRMS relapsing intervals. The PPPM of RRMS patients was 
reduced by $1,139 PPPM when relapsing intervals were increased by 1.5 times 
compared to the usual RRMS relapsing intervals. CONCLUSIONS: The number 
of RRMS patients among MS patients was 87 %. The PPPM of relapses accounted 
for 83% of PPPM of RRMS. By restricting the frequency of relapses it is possible to 
reduce the PPPM of RRMS patients.
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OBJECTIVES: To evaluate the health care resource utilization and costs 
among patients diagnosed with chronic migraine (CM) in the Veterans Health 
Administration (VHA) medical dataset. METHODS: Patients diagnosed with CM 
were identified (International Classification of Diseases, 9th Revision, Clinical 
Modification diagnosis code 346.XX) using the VHA dataset from October 1, 2008 
through September 30, 2010. The initial diagnosis date was designated as the index 
date. Patients without CM with the same age, gender and region (comparison cohort) 
were matched using a randomly chosen index date to minimize selection bias. 
Patients in both cohorts were at least age 18 years and had continuous medical 
and pharmacy benefits for 1 year before and after the index date. One-to-one pro-
pensity score matching (PSM) was used to compare health care costs and utiliza-
tions between the CM and the comparison cohorts, and was adjusted for baseline 
demographic and clinical characteristics. Pain scores were also included to investi-
gate wellness after CM diagnosis. RESULTS: After risk-adjustment by PSM, 123,241 
patients in each cohort were matched. Significantly more CM patients had inpatient 
admissions (6.44% vs. 1.75%, p< 0.0001) and emergency room (ER; 14.42% vs. 5.50%, 
p< 0.0001), outpatient office (68.80% vs. 42.15%, p< 0.0001), outpatient (69.30% vs. 
42.91%, p< 0.0001) and pharmacy visits (70.84% vs. 41.43%, p< 0.0001) compared to 
those without CM. Accordingly, CM patients also incurred higher costs for inpa-
tient admissions and ER, office, outpatient and pharmacy visits compared to those 
without CM. Total costs incurred by CM patients were $4,776, almost triple that of 
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OBJECTIVES: To assess the trends in average wholesaler prices at market entry for 
multiple sclerosis (MS) disease-modifying therapies (DMTs) approved by the US 
Food and Drug Administration (FDA) in the period 1987-2014. METHODS: DMTs 
regulatory information was derived from the FDA website. Average wholesaler 
prices (AWP) per unit at market entry data were derived from the RedBook (Truven 
Health Analytics, Inc.). The AWP history was collected from year of approval to 
October 2014. The daily defined dosage (DDD) for adult patients was obtained 
from FDA approved labels. AWP per DDD and the AWP per year were computed. 
Descriptive statistics and Wilcoxon tests were performed. Statistical significance 
level was set at 0.05. RESULTS: The National Multiple Sclerosis Society listed 11 
FDA approved DMTs (5 new drug applications [NDA] and 6 biological license appli-
cations [BLA]) as of October 2014. Two products were approved by the FDA using 
priority review. The FDA granted orphan designation to 5 DMTs. Only one DMT 
had generic competition in the study period. There was one DMT approved by US 
FDA in the 1980s, three in the 1990s and 2000s, respectively, and 4 in the period 
2010-2014. The median AWP per DDD was $5.88 in the 1980s, $7.13 in the 1990s, 
$217.52 in the 2000s, and $274.76 in the period 2010–Oct 2014. Statistically signifi-
cant differences were found in median AWP per DDD prices between NDAs and 
BLAs. The median AWP per DDD was not significantly different for FDA priority 
review drugs compared to standard review drugs, and for orphan compared to 
non-orphan drugs. CONCLUSIONS: The median AWP per DDD for DMTs at market 
entry increased substantially over time. No statistically significant differences 
were found in the median AWP per DDD between priority and standard review 
drugs, and between orphan and non-orphan drugs.
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OBJECTIVES: To evaluate the economic consequences of having spinal muscular 
atrophy (SMA). METHODS: This study was conducted using Department of Defense 
Military Healthcare System (MHS) data from 2003 to 2012. Eligible persons had a 
SMA diagnosis (ICD-9CM codes 335.0 or 335.1) on 1 inpatient or 3 outpatient claims 
before 18 years of age. Individuals had at least 6 months of data after first SMA 
diagnosis; or died within 6 months after first SMA diagnosis; or had at least 12 
months of data before first SMA diagnosis. Subgroup analyses were conducted for 
early (≤1 years) and late diagnosis (>1 years). RESULTS: A total of 239 individu-
als met the inclusion criteria. The median total expenditure, while enrolled in the 
MHS, was $83,652 (25-75 percentile $29,620-$228,754) over a mean observation of 
6.9±3.6 years, though rare outlier costs were as high as $4.4 million. The mean age 
(SD) at first observed SMA diagnosis was 7.5±6.4 years. The mean (SD) duration of 
observation following initial SMA diagnosis was 4.8±3.3 years with a median cost 
of $60,213 ($18,229-$192,559). For all patients, the primary cost driver was outpa-
tient costs (median $53,152 ($23,902-$136,150)), followed by inpatient costs (median 
$11,258 ($0-$51,987)) and total prescription costs (median $3,167 ($943-$13,283)). 
The subgroup of patients with early diagnosis (n=45) had 4.3±2.9 years of observa-
tion with a median cost of $167,921 ($53,349-$678,412)). Approximately 17.8% of 
this subgroup died during the observation period, which highlights the devastating 
nature of early onset SMA. Patients with late diagnosis (n=194) had 7.5±3.4 years 
observation and median total costs of $70,380 ($28,196-$184,272). CONCLUSIONS: 
Individuals with SMA have a high degree of morbidity and mortality, particularly 
those diagnosed during infancy. SMA patients have significant medical expenditures 
and high utilization of health care services. There is significant economic burden 
caring for patients diagnosed with SMA. DISCLAIMER: Research derived from an IRB 
approved protocol at Naval Medical Center Portsmouth, VA. The views expressed in 
this abstract are those of the authors and do not necessarily reflect the official policy 
or position of the Department of the Army, Department of the Navy, Department of 
Defense or the United States Government. George J. Dahl and Rees Lee are members 
of the U.S. military. This work was prepared as part of their official duties. Title 17 
U.S.C. 105 provides that ‘Copyright protection under this title is not available for any 
work of the United States Government.’ Title 17 U.S.C. 101 defines a United States 
Government work as a work prepared by a military service member or employee of 
the United States Government as part of that person’s official duties.
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Clinical efficacy, utilities and transition probabilities were derived from published 
studies. Resource costs were estimated from 656 individual patient level data from 
Adelphi 2012 UK patient dataset, using Irish costs, where possible. Time horizon 
was 20 years and patients were followed until death if it occurred earlier. Costs 
and outcomes were discounted at 4%. Both one-way and probabilistic sensitivity 
analyses were conducted.. RESULTS: The incremental cost-effectiveness ratio for 
LCIG vs. SOC was € 41,114/QALY (total costs LCIG vs. SoC are € 537,276 vs. € 465,716 
and QALYs are 4.72 vs. 2.98). LCIG is cost-effective at a payer threshold of € 45,000. 
The model is most sensitive to health state costs. CONCLUSIONS: LCIG is a cost-
effective option in treating APD patients in Ireland.
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OBJECTIVES: To compare the cost-effectiveness of current disease modifying thera-
pies (DMT) for patients with relapsing-remitting multiple sclerosis (RRMS) in the 
US. METHODS: An economic model was created to predict the course of patients 
with RRMS following initiation of a DMT. Natalizumab (NAT), dimethyl fumarate 
(DMF), and peginterferon beta-1a (PEG), were compared with fingolimod (FIN), glati-
ramer acetate (GA, 40 milligrams thrice weekly), and interferon beta-1a (INT, 44 
micrograms thrice weekly), respectively. The Markov state transition cohort model 
predicted disease progression across RRMS Expanded Disability Status Scale [EDSS] 
states and for secondary-progressive (SPMS) EDSS states in 3-month cycles over a 
10-year time horizon. The patient cohort was at risk of death, relapse, or discontinu-
ation (due to reaching EDSS level 7, or following DMT-specific rates) in each cycle. 
Outcome measures were relapses, relapse-free time, MS progression, and progres-
sion and clinical disease activity-free years. Costs included drug, administration, 
monitoring, relapse, and EDSS state costs. Incremental cost-effectiveness ratios 
(ICERs) were estimated for each of the outcome measures. RESULTS: Costs ranged 
from $477,158 (DMF) to $526,667 (INT). NAT, DMF, and PEG were less expensive with 
equal, or better, outcomes. NAT and DMF were dominant (less costly and more 
effective) compared to FIN and GA, respectively, for all ICERs. PEG dominated INT 
on progression and clinical disease activity outcomes. Comparable relapse-related 
outcomes cost more than $30,000 with INT compared to PEG. Variability in drug 
costs and parameters that affected drug cost accrual (eg, discontinuation rates 
and the decision to drop out after SPMS conversion) had a considerable impact on 
ICERs. CONCLUSIONS: Results from this analysis suggest that the NAT, DMF and 
PEG are cost-effective DMT choices compared to FIN, GA, and INT, respectively. The 
actual impact to a particular plan will vary based on drug pricing and other factors 
affecting drug cost accrual.
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OBJECTIVES: To analyze cost effectiveness of amitriptyline and propranolol in the 
management of migraine METHODS: A total of 60 patients with migraine were 
enrolled, into the Prospective, observational, exploratory study based on the inclu-
sion and exclusion criteria. Migraine headache frequency, duration and used of over 
the counter drugs per month migraine headache pain score and headache impact 
test score were assessed and recorded at baseline by using a suitably designed ques-
tionnaire and headache impact test questionnaire. The patients were given either 
amitriptyline or propranolol . After the completion of one month of drug therapy 
score of patients were measured using the same questionnaire and in addition cost 
of prescription drugs and over the counter drugs were calculated.The effectiveness 
of treatment on patients was evaluated by comparing the mean scores before and 
after treatment by applying paired sampled T- test and independent sample test to 
compare means between the two treatment groups. Cost effectiveness analysis was 
done in terms of reduction of headache frequency per month before and after the 
treatment . RESULTS: The result showed that to prevent single migraine headache 
patient under amitriptyline group has to pay NRs.8.897 on the drugs (amitriptyline 
and analgesic)where patient under Propranolol group has to pay NRs.30.11 on the 
drugs (propranolol and analgesic) to prevent single migraine headache. In addi-
tion the study suggests using either amitriptyline or propranolol for treatment of 
migraine headache is same in terms of reduction of headache frequency and in 
terms of reduction of headache duration. However amitriptyline was found supe-
rior to propranolol in terms of reduction of headache impact test score and used of 
over the counter drugs. But propranolol was found to significantly lower headache 
pain score compare to amitriptyline. CONCLUSIONS: Amitriptyline is the most cost 
effective option when compared to propranolol in migraine.
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OBJECTIVES: Compare the cost-efectiveness (CE) of levodopa, pramipexole, rasagil-
ine and selegiline in patients with early Parkinson’s disease from the perspective 
of National Institute of Neurology and Neurosurgery (NINN) in Mexico. METHODS: 
We developed a CE model, that linked Unified Parkinson’s Disease Rating Scale 
(UPDRS) Parts II (activities of daily life) and III (motor) scores to disease progres-
sion and direct costs (drugs, medical appointments, adverse events, and labora-
tory studies), which were obtained of clinical records and unit cost of NINN. Data 
used in the model were obtained from clinical trials and we developed an indirect 
patients without CM ($1,756). There were more CM patients with accompanying pain 
at all levels (mild: 19.53% vs. 0.16%; moderate: 13.10% vs. 0.10%; severe: 16.20% vs. 
0.12%; all p< 0.0001). CONCLUSIONS: CM patients in the VHA population had sub-
stantial health care resource utilization, incurred higher costs and suffered worse 
pain compared to those without the disease.
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OBJECTIVES: To examine the health care resource utilizations and costs among 
migraine patients in the U.S. Medicaid population. METHODS: Migraine patients 
were identified (International Classification of Disease, 9th Revision, Clinical 
Modification [ICD-9-CM] diagnosis code 346) using Medicaid data from January 01, 
2009 through December 31, 2009. The first diagnosis date was designated as the 
index date, and patients were required to have at least a 1-year baseline (pre-index 
date) and 1-year follow-up (post-index date) period. A comparison cohort was cre-
ated for patients without a migraine diagnosis during the study period, using 1:1 
propensity score matching to control for age, region, gender and baseline Charlson 
Comorbidity Index score. The comparison cohort’s index date was chosen at ran-
dom to minimize selection bias. Patients in both cohorts were required to be age 
≥ 18 years and have continuous medical and pharmacy benefits 1-year pre- and 
post-index date. Study outcomes (health care resource utilizations and costs) were 
compared between the migraine and comparison cohorts. RESULTS: After applying 
PSM, 380,751 patients were assigned to each cohort, and baseline characteristics 
were well-balanced. A higher percentage of patients with migraines had inpatient 
stays (21.53% vs. 11.00%, p< 0.0001), other therapy (99.88% vs. 65.78%, p< 0.001) and 
pharmacy visit claims (90.52% vs. 48.35%, p< 0.0001), compared to those without a 
migraine diagnosis. The patients in the migraine cohort also incurred significantly 
higher other therapy ($4,111 vs. $2,312, p< 0.0001) and pharmacy visit costs ($1,074 
vs. $512, p< 0.0001) than those in the comparison cohort. CONCLUSIONS: Migraine 
patients incurred significantly higher costs and had higher health care resource 
utilizations than those without migraines.
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OBJECTIVES: Parkinson’s disease (PD) is a progressive disease associated with 
substantial economic and societal burden. Immediate-release (IR) carbidopa-levo-
dopa (CD-LD) is the gold standard in treatment for advanced PD patients. However, 
effectiveness of IR CD-LD diminishes with long-term treatment and is associated 
with increased “off” time (re-emergence of PD symptoms) and the advent of motor 
complications. CD-LD plus entacapone (CL+E) has produced some clinical improve-
ment over IR CD-LD alone. IPX066 is an extended-release oral formulation of CD-LD 
designed to address some of the limitations of IR CD-LD by rapidly attaining and 
maintaining therapeutic LD concentrations for a prolonged duration. The aim of 
the study was to evaluate the comparative cost-effectiveness of IPX066 against 
CL+E. METHODS: A Markov model was developed comparing IPX066 with branded 
and generic CL+E in the US market. Health states included ≤ 25% “off” time, > 25% 
“off” time, and dead. The model simulated a hypothetical patient’s progression over 
a 5-year period through these health states, with a 6-month Markov cycle length. 
Outcomes evaluated were total direct costs, quality-adjusted life years (QALYs), 
and incremental cost-effectiveness ratios (ICER). Dosing and efficacy data from 
a Phase 3 study comparing IPX066 and CL+E, average wholesale acquisition drug 
costs (RedBook), and published literature were utilized for this evaluation. Non-2014 
costs were inflated to reflect the 2014 value using the medical component of the 
Consumer Price Index. The discount rate employed was 3%. RESULTS: IPX066 was 
dominant over both branded and generic CL+E therapies, with ICERs of (-$166,044) 
and (-$75,920), respectively. On average, patients who received IPX066 experienced 
a 5.1% increase in QALYs (2.90) compared with patients who did not receive IPX066 
(2.76). IPX066 dominated the other two therapies throughout multiple sensitivity 
analyses, driven largely by improved effectiveness of IPX066. CONCLUSIONS: IPX066 
is likely to be a cost-effective therapy in patients with advanced PD.
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BACkgROUND: Parkinson’s disease (PD) is an incurable, progressive neurological 
disease, with primary symptoms impacting movement, walking and posture; that 
eventually become severely disabling. Advanced PD (APD) has a significant impact 
on Quality of Life (QoL) for patients, their carer’s/families. Levodopa/Carbidopa 
intestinal gel (LCIG) is indicated for the treatment of advanced levodopa-responsive 
Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when 
available combinations of Parkinson medications have not given satisfactory results. 
There are no published studies reporting the economic value of LCIG in treatment 
of patients with APD in Ireland. OBJECTIVES: Determine the cost-effectiveness of 
LCIG compared with Standard of care (SoC) for the treatment of APD patients in 
Ireland METHODS: A deterministic Markov model was used to evaluate LCIG vs. 
SoC in APD patients with severe motor fluctuations from an Irish health care per-
spective. The model simulated a cohort of 100 patients and redistributed them into 
disease-specific health states. Health states were defined by Hoehn & Yahr (H&Y) 
scale combined with amount of time in OFF-time. SoC comprised of standard oral 
therapy +/- sub-cutaneous apomorphine infusion and standard follow up visits. 
